Cellceutix Corp. (CTIX.OB) Completes Successful Meeting with FDA for Cancer Drug
Cellceutix Cop. is a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease. The company announced today that it has completed a successful pre-investigational new drug exemption (pre-IND) meeting with the US Food and Drug Administration (FDA) for its lead compound, Kevetrin, which is being developed to treat drug resistant cancers. The company has the remaining pre-IND animal studies for Kevetrin underway. These studies consist of intermediate-term toxicity studies in two species and safety pharmacology studies in the cardiovascular, central nervous system and respiratory areas. In these animal studies, Kevetrin was found to significantly delay tumor growth…